Treats metastatic carcinoid tumors. ANDA 203765, held by Heritage. Octreotide Acetate.
As of Nov 16, 2026, ANDA 203765 (Octreotide Acetate), held by Heritage, was first approved by FDA on Sep 7, 2018, with 4 approved supplements and 0 published complete response letters.
Octreotide acetate injection is a somatostatin analogue indicated:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 7, 2018 | Original application | Approved | None posted |
| Octreotide AcetateEQ 0.2MG BASE/ML · injectable;injection | Octreotide Acetate | Rx |
| Octreotide AcetateEQ 1MG BASE/ML · injectable;injection | Octreotide Acetate | Rx |
| Jul 9, 2024 | Supplement 6Labeling · Standard review | Approved | None posted |
| Feb 21, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 21, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 3, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 7, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters